Novo Nordisk A S annual net income
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Net Income Growth & History (NVO)
Novo Nordisk A S's net income was kr102.43B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr102.43B | kr1.45B | +1.43% |
| 2024 | 2024-12-31 | kr100.99B | kr17.30B | +20.68% |
| 2023 | 2023-12-31 | kr83.68B | kr28.16B | +50.71% |
| 2022 | 2022-12-31 | kr55.52B | kr7.77B | +16.27% |
| 2021 | 2021-12-31 | kr47.76B | kr5.62B | +13.33% |
| 2020 | 2020-12-31 | kr42.14B | kr3.19B | +8.18% |
| 2019 | 2019-12-31 | kr38.95B | — | — |
Novo Nordisk A S quarterly net income
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr20.99B | −kr5.51B | −20.81% |
| Q1 2026 | 2026-03-31 | kr48.56B | kr19.52B | +67.24% |
| Q4 2025 | 2025-12-31 | kr26.89B | −kr1.34B | −4.74% |
| Q3 2025 | 2025-09-30 | kr20.01B | −kr7.29B | −26.72% |
| Q2 2025 | 2025-06-30 | kr26.50B | kr6.45B | +32.18% |
| Q1 2025 | 2025-03-31 | kr29.03B | kr3.63B | +14.28% |
| Q4 2024 | 2024-12-31 | kr28.23B | — | — |
| Q3 2024 | 2024-09-30 | kr27.30B | — | — |
| Q2 2024 | 2024-06-30 | kr20.05B | — | — |
| Q1 2024 | 2024-03-31 | kr25.41B | — | — |
Novo Nordisk A S net income trends
Over the last five fiscal years, Novo Nordisk A S's net income increased from kr42.14B to kr102.43B, a change of kr60.30B. The latest reported quarter, Q2 2026, shows kr20.99B.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...